Insmed has secured FDA approval for Brinsupri (brensocatib), the first dipeptidyl peptidase 1 inhibitor indicated for treating non-cystic fibrosis bronchiectasis (NCFB), a chronic lung condition with significant unmet needs. The drug demonstrated efficacy in reducing exacerbations and received FDA clearance for adult and adolescent patients. Insmed envisions blockbuster sales, estimating peak revenue potential of $5 billion. The company is pursuing approvals in Europe, the UK, and Japan and highlights the drug’s novel mechanism targeting neutrophil activation, addressing inflammation in bronchiectasis.